医学会议分类导航
 
 
领域国际医学会议网公众号
 
首页  
2021年第63届美国放射肿瘤学会年会(ASTRO)
     
 
 

◆ 会议时间:2021年10月24日至27日
◆ 会议地点:美国 芝加哥/Chicago - McCormick Place West


◆ 会议简介:

2021年第63届美国放射肿瘤学会(ASTRO)年会将于2021年10月24日至27日在美国伊利诺伊州芝加哥举行。ASTRO年会(美国放疗年会)是世界放射肿瘤学界最重要的年度会议,每年都会吸引超过10,000名来自世界各地的相关专业人士前来参会。

美国放射肿瘤学会(ASTRO)成立于1958年,是世界上首屈一指的放射肿瘤学组织。ASTRO现拥有超过10000名会员,包括医生、护士、生物学家、物理学家、放疗技师、剂量师和其他专业从事放谢治疗的医疗保健专业人员。 作为领先的放射肿瘤学组织,ASTRO致力于通过专业的教育和培训,支持临床实践和卫生政策标准,促进科学研究和宣传等手段改善对患者的护理。——未经本站允许,禁止复制摘录转载本站任何内容-领域国际医学会议网。

WELCOME TO THE 63RD ASTRO ANNUAL MEETING

The theme for the meeting, “Embracing Change, Advancing Person-Centered Care,” highlights the importance of embracing the rapid advancements in the field of radiation oncology to provide the best patient care in the most efficient way. The theme will also touch on the need to focus on the whole patient in the treatment plan, as well as on the well-being of our health care workers — physicians, nurses, physicists, and all the members of the treatment team.

We invite you to share your research at this prestigious scientific gathering. If accepted, you will have the opportunity to present your abstract to peers from around the world, and abstracts will be published in a supplement to the Red Journal and made available to readers worldwide via redjournal.org.

 

ASTRO 2021 摘要提交时间:
Deadline to Submit: Monday, March 1, 2021, at 11:59 p.m. Pacific time
Notifications of acceptance or decline: Wednesday, May 12, 2021

点此提交摘要>>>Submit Abstract>>>

Eligibility

  1. Sponsorship or ASTRO membership is not required to submit an abstract.
  2. Abstracts must be received by 11:59 p.m. Pacific time, Monday, March 1, 2021. 
  3. All studies in oncology, radiation oncology and radiation-therapy for non-oncologic conditions is eligible for submission. This includes basic and translational science, technology-related, health services research, epidemiologic, patient-focused clinical studies and all phases of trials.
  4. An abstract may only be submitted once. Abstracts of clinically-related subjects should be combined into a single abstract. Submission of multiple abstracts on a single study may result in the rejection of one or more abstracts.
  5. Submit new research. Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown. 
  6. Obligation to Register: Acceptance of the abstract by the committee obligates the author to present the paper and pay the meeting registration fee. If circumstances prevent attendance, you must notify ASTRO and arrange for an alternate presenter, preferably a co-author in the Speaker Center. If you do not register and attend the meeting, your abstract will be removed from the program.
  7. Disclosures: The submitter must complete the disclosures for the presenter and all co-authors. Use this form to gather all co-author information and use it when entering the co-authors into the abstract submission site.

Important Deadlines

  1. Abstracts must be received by 11:59 p.m. Pacific Time, Monday, March 1, 2021. Abstracts may be edited up until the deadline. Abstracts will be considered ineligible for review if they are incomplete. Abstracts that are unpaid or have payment issues will not be considered. If you do not receive a confirmation receipt, follow up with ASTRO to confirm your “complete” status.
  2. Revisions: Please proof your abstract carefully for formatting, spelling and data errors. Pay special attention to the author order and presenting author designation. Review your confirmation email, as this is how the abstract will be published. Errors can be corrected if sent to ASTRO by July 1, 2021. After this date, we cannot make any corrections. This rule is strictly enforced.
  3. Notifications: You will be notified via email of the disposition of your abstract by May 12, 2021. Notifications are sent to the person listed as the “presenting” author.
  4. Withdrawals: If you choose to withdraw your abstract, please change your decision to “withdraw” in the Speaker Center by July 1, 2021, and notify ASTRO staff via email. After this date, your abstract will be published exactly as it was submitted in the International Journal of Radiation Oncology • Biology • Physics (Red Journal).
  5. Submission of an abstract conveys permission to be posted online and printed in the International Journal of Radiation Oncology • Biology • Physics (Red Journal) (www.redjournal.org)

Presenting Author Responsibility

  1. An individual may submit more than one abstract in which he or she is indicated as the first author, but he or she may only present one oral presentation. If more than one abstract is selected for oral presentation, an alternate presenter must be assigned, preferably a co-author (this does not apply to poster presentations).
  2. It is the submitter’s responsibility to ensure up-to-date and accurate disclosures are submitted for each co-author on the abstract. ASTRO manages and reports all disclosures as submitted. Potential conflicts with commercial interest for the presenting author and all co-authors must be disclosed at the time of submission.
  3. The presenting author will receive all notifications and email communications related to the accepted abstract(s), and is responsible for informing all co-authors of acceptance to ASTRO’s Annual Meeting.
  4. ASTRO has developed a policy to handle any violations to the ASTRO Disclosure policy. Any reported violations will be researched and handled according to policy, which can include removal from presenting at future conferences.
  5. Obligation to Register: Acceptance of the abstract by the committee obligates the author to present the paper and pay the meeting registration fee. If circumstances prevent attendance, you must notify ASTRO and arrange for an alternate presenter, preferably a co-author. If the presenting author does not register and attend the meeting, your abstract will be removed from the program.

Presentation at Other Meetings

  1. Abstracts should contain new material that has not been presented or published prior to the ASTRO Annual Meeting, October 24 - 27, 2021. Previously presented abstracts will not be eligible for ASTRO’s official Press Program or Plenary Session.
  2. Abstract presenters with the same abstract accepted for presentation at another major medical meeting* or accepted for publication after March 1, 2021, are required to notify ASTRO's Education Team. The Scientific Committee will review and decide on a case-by-case basis if it will remain in the program.

Properly Formatted Abstract

  1. Abstracts must be properly formatted and organized into four sections identified by the following bolded headers: Purpose/Objectives, Materials/Methods, Results and Conclusions.
  2. Abstracts should include a scientific hypothesis in the Purpose/Objectives section, and implications for research, policy or practice in the Conclusions section, when applicable.
  3. Presentations must give a balanced view of therapeutic options. Brand names of pharmaceuticals and trade names of medical devices cannot be used in the title or body of the abstract. ASTRO reserves the right to replace proprietary names with generic names.
  4. Institution names should not be included in the title or body of the abstract. Alternative language is “at one institution” or “a multi-institution” study, etc. This does not apply to cooperative research group names. 
  5. The title should not include results. 
  6. The abstract cannot contain illustrations, images or graphs. If the abstract is accepted, presenters may include these items in their on-site presentations.
  7. An abstract may contain one small table. The maximum character limit, including the title and body of the abstract, is 2,600 characters. Spaces are not counted.
  8. A maximum of 20 authors’ names may be listed on each abstract. There are no exceptions. Authorship credit should only be given if all three of the following criteria are met. There is not mechanism for listing co-lead authors, or co-PI’s. Each author must have made substantial contributions to:
  • conception and design, or analysis and interpretation of data, and
  • drafting the abstract or revising it critically for important intellectual content, and
  • final approval of the version to be submitted/published.

Special Physics Session

There will be a special Physics subcategory which will solicit cutting edge research that will exemplify this theme: “Advances in Stereotactic and Hypofractionated Response Modeling and Treatments.” Abstracts for this subcategory will be reviewed and selected by an independent panel of experts and presented in an oral session.

Special Biology Session

There will be a special Biology subcategory which will solicit cutting edge research that will exemplify this theme: “Innovative Biologic Approaches to Personalize Radiotherapy.” Abstracts for this subcategory will be reviewed and selected by an independent panel of experts and presented in an oral session.

Interim Analysis

  1. In general, ASTRO does not accept abstracts reporting an interim analysis that is intended to evaluate experimental treatment regimen(s) with respect to efficacy or safety at any time prior to formal completion of a trial.
  2. Abstracts reporting trial process updates, such as accrual, baseline characteristics, and non-protocol specific safety information, will be considered for posters only for promotional purposes.

Database Studies

  1. Retrospective registry databases, such as National Cancer Database (NCDB), Surveillance, Epidemiology and End Results (SEER), etc., are valuable resources for patterns of care assessment, and may generate important evidence for comparative effectiveness research.
  2. For comparative effectiveness reports, prioritization will be given to those when the level 1 evidence from randomized trials is obsolete or difficult to obtain. Abstracts should include brief descriptions on statistical methods and justifications, such as the choice of statistical significance level, effect size, methods for confounding adjustment, etc., to facilitate proper interpretations.

 

 


ASTRO 2021年美国放疗年会-ASTRO放射治疗肿瘤年会-ASTRO放射年会-美国放射肿瘤学年会


 

◆ 参会对象:
放射科医师,肿瘤科医师,护士,生物学家,物理学家,放疗技师,放射剂量师,药疗企业代表,以及其他相关卫生保健专业人士等等。

 
 
※相关服务※
会议注册服务:30美金起/人/次(服务费)+ 会议注册费(按官方规定收取,注册类别请咨询客服);
出境签证服务:1500元人民币/人/次(美国,含签证费),其它国家咨询客服;
大会投稿服务:30美金/人/次,官方收取费用另计(如有);
会员申请服务:30-100美金/人/次;

团组参会、行程定制,以及需要其它服务(如接送机等),请直接联系客服。


 
咨询报名:
李老师
400-089-1003(微信扫描右侧二维码咨询)
 
 
领域国际医学会议网——专注专业的国际医学会议服务商,专业服务医学相关群体!
 
  领域国际医学会议网介绍/联系  
版权所有:领域国际医学会议网 未经许可禁止复制转载摘录镜像本站任何内容! 隐私政策/版权/免责声明 | 联系我们